INGN

+ Watchlist + Portfolio

Inogen, Inc

Regulated industry Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.98
52-Week Range: $5.05 – $9.13
Market Cap: $158.43M
P/E (TTM): —
EPS (TTM): -0.92
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.91
PEG Ratio: —
Return on Equity: -13.14%
Return on Assets: -5.84%
Gross Margin: 44.51%
Operating Margin: -5.13%
Profit Margin: -6.94%
Current Ratio: 2.74
Debt/Equity: 0.09
Total Debt: $15.79M
Free Cash Flow: $-1.77M
Revenue Growth: 3.00%
Earnings Growth: —
Enterprise Value: $68.69M

INGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$377.24M	$315.66M	$335.70M	$348.67M
Cost of Revenue	$223.71M	$188.96M	$180.96M	$194.40M
Gross Profit	$153.53M	$126.70M	$154.74M	$154.26M
Research & Development	$21.94M	$20.84M	$21.61M	$19.40M
Selling, General & Admin	$164.67M	$182.35M	$175.65M	$165.07M
Operating Expenses	$186.62M	$203.19M	$197.26M	$184.47M
Operating Income	-$33.08M	-$76.49M	-$42.52M	-$30.21M
EBITDA	-$9.57M	-$58.34M	-$21.51M	-$9.55M
Pretax Income	-$83.27M	-$102.34M	-$36.48M	-$23.38M
Income Tax	$504.00K	$105.00K	-$588.00K	-$632.00K
Net Income	-$83.77M	-$102.45M	-$35.89M	-$22.75M
Diluted EPS	-3.67	-4.42	-1.52	-0.86
Diluted Shares	22.85M	23.18M	23.65M	26.60M

INGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$187.01M	$125.49M	$113.80M	$103.73M
Receivables	$64.35M	$42.91M	$29.56M	$38.86M
Inventory	$34.09M	$21.84M	$24.81M	$25.97M
Current Assets	$304.64M	$207.07M	$185.45M	$198.30M
Total Assets	$405.04M	$326.19M	$296.19M	$298.63M
Current Liabilities	$65.35M	$72.50M	$76.69M	$63.53M
Total Debt	$23.28M	$21.92M	$19.41M	$17.48M
Total Liabilities	$107.64M	$121.38M	$122.33M	$106.39M
Retained Earnings	-$14.50M	-$116.95M	-$152.84M	-$175.58M
Shareholders' Equity	$297.41M	$204.81M	$173.86M	$192.23M
Working Capital	$239.30M	$134.57M	$108.77M	$134.76M

INGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$37.53M	-$3.23M	$5.91M	-$11.22M
Capital Expenditure	-$21.22M	-$27.01M	-$17.09M	-$10.38M
Free Cash Flow	-$58.75M	-$30.25M	-$11.18M	-$21.60M
Depreciation & Amortisation	$23.51M	$18.15M	$21.00M	$20.66M
Stock-Based Compensation	$12.28M	$7.43M	$7.40M	$8.01M
Investing Cash Flow	-$10.88M	-$59.31M	-$13.97M	-$26.21M
Financing Cash Flow	$380.00K	$960.00K	$265.00K	$24.18M
Net Change in Cash	-$48.03M	-$61.59M	-$7.80M	-$13.24M

INGN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$82.28M	$92.28M	$92.39M	$81.72M	$85.11M	$95.08M
Cost of Revenue	$45.91M	$50.94M	$51.07M	$46.48M	$47.25M	$51.81M
Gross Profit	$36.37M	$41.34M	$41.32M	$35.24M	$37.86M	$43.27M
Research & Development	$4.03M	$5.21M	$4.84M	$5.32M	$5.10M	$5.87M
Selling, General & Admin	$39.99M	$42.26M	$43.59M	$39.23M	$42.10M	$42.50M
Operating Expenses	$44.03M	$47.47M	$48.43M	$44.54M	$47.20M	$48.37M
Operating Income	-$7.66M	-$6.13M	-$7.12M	-$9.31M	-$9.34M	-$5.10M
EBITDA	-$2.47M	-$913.00K	-$1.90M	-$4.27M	-$4.43M	-$399.00K
Pretax Income	-$6.27M	-$4.30M	-$5.44M	-$7.36M	-$8.50M	-$4.00M
Income Tax	-$97.00K	-$153.00K	-$146.00K	-$236.00K	-$174.00K	-$154.00K
Net Income	-$6.17M	-$4.15M	-$5.29M	-$7.13M	-$8.32M	-$3.85M
Diluted EPS	-0.25	-0.15	-0.20	-0.26	-0.30	-0.14
Diluted Shares	25.16M	26.96M	27.08M	27.18M	27.32M	27.05M

INGN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$118.89M	$103.69M	$106.48M	$103.73M	$93.11M	$87.28M
Receivables	$36.62M	$38.59M	$40.37M	$38.86M	$41.87M	$46.16M
Inventory	$26.27M	$24.31M	$25.07M	$25.97M	$24.99M	$28.63M
Current Assets	$200.71M	$203.12M	$203.72M	$198.30M	$190.66M	$194.14M
Total Assets	$308.41M	$312.04M	$307.01M	$298.63M	$285.93M	$285.57M
Current Liabilities	$65.45M	$67.07M	$64.94M	$63.53M	$61.45M	$70.86M
Total Debt	$19.21M	$19.04M	$18.22M	$17.48M	$16.93M	$15.79M
Total Liabilities	$110.46M	$112.55M	$109.83M	$106.39M	$103.02M	$110.71M
Retained Earnings	-$159.01M	-$163.16M	-$168.46M	-$175.58M	-$183.91M	-$187.76M
Shareholders' Equity	$197.95M	$199.49M	$197.18M	$192.23M	$182.91M	$174.86M
Working Capital	$135.26M	$136.05M	$138.77M	$134.76M	$129.22M	$123.27M

INGN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.79M	$4.35M	$2.17M	-$943.00K	-$6.68M	$2.95M
Capital Expenditure	-$2.04M	-$3.87M	-$2.10M	-$2.37M	-$781.00K	-$1.92M
Free Cash Flow	-$18.83M	$480.00K	$64.00K	-$3.31M	-$7.47M	$1.03M
Depreciation & Amortisation	$5.19M	$5.22M	$5.22M	$5.04M	$4.90M	$4.70M
Stock-Based Compensation	$2.15M	$2.29M	$1.76M	$1.81M	$1.95M	$1.77M
Investing Cash Flow	-$2.04M	-$22.57M	-$82.00K	-$1.52M	-$1.98M	-$3.13M
Financing Cash Flow	$23.95M	$0.00	$418.00K	-$187.00K	-$2.12M	-$5.62M
Share Repurchases	$0.00	$0.00	—	—	-$1.87M	-$5.62M
Net Change in Cash	$5.12M	-$18.22M	$2.50M	-$2.65M	-$10.78M	-$5.81M

Market Snapshot

About

Inogen, Inc. is a medical technology company that develops, manufactures, and markets innovative oxygen concentrators for patients suffering from chronic respiratory conditions. The company's flagship products are portable oxygen concentrators that allow patients greater freedom and mobility compared to traditional oxygen tanks. Inogen's oxygen therapy systems are used by patients with chronic obstructive pulmonary disease (COPD), emphysema, and other respiratory diseases requiring supplemental oxygen. The company sells its products directly to patients and through home medical equipment providers in the United States and internationally.